Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23827935 | 1.00 | POLRMT (0.43) | POLRMTDOT1LRIPK1CYP3A4CYP2C9 | |
| SCHEMBL23844035 | 0.93 | POLRMT (0.41) | POLRMTDOT1LRIPK1CYP3A4CYP2C9 | |
| SCHEMBL23827960 | 0.93 | POLRMT (0.43) | POLRMTDOT1LRIPK1CYP3A4CYP2C9 | |
| SCHEMBL23827966 | 0.93 | POLRMT (0.43) | POLRMTDOT1LRIPK1CYP3A4CYP2C9 | |
| SCHEMBL23827933 | 0.93 | POLRMT (0.43) | POLRMTDOT1LRIPK1CYP3A4CYP2C9 | |
| SCHEMBL23827939 | 0.93 | POLRMT (0.43) | POLRMTDOT1LRIPK1CYP3A4CYP2C9 | |
| SCHEMBL23827937 | 0.93 | POLRMT (0.43) | POLRMTDOT1LRIPK1CYP3A4CYP2C9 | |
| SCHEMBL23827958 | 0.93 | POLRMT (0.43) | POLRMTDOT1LRIPK1CYP3A4CYP2C9 | |
| SCHEMBL23844137 | 0.90 | POLRMT (0.43) | POLRMTDOT1LRIPK1CYP3A4CYP2C9 | |
| SCHEMBL23844104 | 0.89 | POLRMT (0.42) | POLRMTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4106876-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | POLRMT 76/4885DOT1L 653/4885RIPK1 3546/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | POLRMT 76/4885DOT1L 653/4885RIPK1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.